Factors impacting unbound vancomycin concentrations in neonates and young infants

[1]  V. Stove,et al.  Impact of vancomycin protein binding on target attainment in critically ill children: back to the drawing board? , 2016, The Journal of antimicrobial chemotherapy.

[2]  K. Oselin,et al.  Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target? , 2016, BMC Pediatrics.

[3]  E. Starkey,et al.  What do I need to know about glycopeptide antibiotics? , 2016, Archives of Disease in Childhood: Education & Practice Edition.

[4]  S. Sutçuoglu,et al.  Reference values of serum IgG and IgM levels in preterm and term newborns , 2016, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[5]  P. Desai,et al.  Evaluation of Vancomycin Use in Late-Onset Neonatal Sepsis Using the Area Under the Concentration–Time Curve to the Minimum Inhibitory Concentration ≥400 Target , 2015, Therapeutic drug monitoring.

[6]  P. Vermeersch,et al.  Factors Impacting Unbound Vancomycin Concentrations in Different Patient Populations , 2015, Antimicrobial Agents and Chemotherapy.

[7]  J. N. van den Anker,et al.  How to use vancomycin optimally in neonates: remaining questions , 2015, Expert review of clinical pharmacology.

[8]  A. Verstraete,et al.  Measuring Unbound Versus Total Vancomycin Concentrations in Serum and Plasma: Methodological Issues and Relevance , 2015, Therapeutic drug monitoring.

[9]  Steven Pauwels,et al.  Novel LC-MS/MS method for plasma vancomycin: comparison with immunoassays and clinical impact. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[10]  A. Tonna,et al.  Neonatal vancomycin trough level audit using British National Formulary for Children dosing , 2014, Archives of Disease in Childhood: Fetal and Neonatal Edition.

[11]  D. Pajkrt,et al.  Inadequate vancomycin therapy in term and preterm neonates: a retrospective analysis of trough serum concentrations in relation to minimal inhibitory concentrations , 2014, BMC Pediatrics.

[12]  A. Smits,et al.  Prospective validation of neonatal vancomycin dosing regimens is urgently needed , 2014, Current therapeutic research, clinical and experimental.

[13]  S. Wicha,et al.  Unbound fraction of vancomycin in intensive care unit patients , 2014, Journal of clinical pharmacology.

[14]  A. Smits,et al.  Cefazolin plasma protein binding in different human populations: more than cefazolin-albumin interaction. , 2014, International journal of antimicrobial agents.

[15]  D. Nicolau,et al.  Clinical Laboratory–Based Assay Methodologies May Underestimate and Increase Variability of Vancomycin Protein Binding in Hospitalized Patients , 2014, Pharmacotherapy.

[16]  P. Nordmann,et al.  Emergence of OXA-72-producing Acinetobacter pittii clinical isolates. , 2014, International journal of antimicrobial agents.

[17]  P. Tulkens,et al.  mplementation of a protocol for administration of vancomycin by ontinuous infusion : pharmacokinetic , pharmacodynamic and oxicological aspects , 2013 .

[18]  B. Guglielmo,et al.  Every 36-hour Gentamicin Dosing in Neonates with Hypoxic Ischemic Encephalopathy Receiving Hypothermia , 2013, Journal of Perinatology.

[19]  H. Sammons,et al.  Vancomycin use in neonates and children: evidence-based practice is needed , 2013, Archives of Disease in Childhood.

[20]  P. Vermeersch,et al.  Cefazolin plasma protein binding and its covariates in neonates , 2012, European Journal of Clinical Microbiology & Infectious Diseases.

[21]  K. Allegaert,et al.  Clinical pharmacokinetics of vancomycin in the neonate: a review , 2012, Clinics.

[22]  Nimish Patel,et al.  Refining Vancomycin Protein Binding Estimates: Identification of Clinical Factors That Influence Protein Binding , 2011, Antimicrobial Agents and Chemotherapy.

[23]  O. Cars,et al.  Protein Binding: Do We Ever Learn? , 2011, Antimicrobial Agents and Chemotherapy.

[24]  J. Rello,et al.  The Effects of Hypoalbuminaemia on Optimizing Antibacterial Dosing in Critically Ill Patients , 2011, Clinical pharmacokinetics.

[25]  Stephan Schmidt,et al.  Significance of protein binding in pharmacokinetics and pharmacodynamics. , 2010, Journal of pharmaceutical sciences.

[26]  P. Tulkens,et al.  International Journal of Antimicrobial Agents Correlation between Free and Total Vancomycin Serum Concentrations in Patients Treated for Gram-positive Infections , 2022 .

[27]  F. V. van Tiel,et al.  Protein Binding of Flucloxacillin in Neonates , 2007, Therapeutic drug monitoring.

[28]  J. N. van den Anker,et al.  Vancomycin: pharmacokinetics and administration regimens in neonates. , 2004, Clinical pharmacokinetics.

[29]  W. Poole,et al.  Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. , 2002, Pediatrics.

[30]  E. Lee,et al.  Pharmacokinetics of Intravenous Vancomycin in Patients with End‐Stage Renal Failure , 1990, Therapeutic drug monitoring.

[31]  J. Rotschafer,et al.  The influence of serum albumin and alpha 1-acid glycoprotein on vancomycin protein binding in patients with burn injuries. , 1989, The Journal of burn care & rehabilitation.

[32]  J. Rotschafer,et al.  Vancomycin pharmacokinetics in patients with various degrees of renal function , 1988, Antimicrobial Agents and Chemotherapy.

[33]  B. Ackerman,et al.  Vancomycin Serum Protein Binding Determination by Ultrafiltration , 1988, Drug intelligence & clinical pharmacy.

[34]  M. Ballow,et al.  Development of The Immune System in Very Low Birth Weight (Less than 1500 g) Premature Infants: Concentrations of Plasma Immunoglobulins and Patterns of Infections , 1986, Pediatric Research.

[35]  J. Roberts,et al.  The Clinical Relevance of Plasma Protein Binding Changes , 2012, Clinical Pharmacokinetics.

[36]  N. Holford,et al.  Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. , 2007, British journal of clinical pharmacology.

[37]  K. Sunakawa,et al.  In vitro protein binding of teicoplanin to neonatal serum , 2004, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[38]  L. Notarianni.  Plasma Protein Binding of Drugs in Pregnancy and in Neonates , 1990, Clinical pharmacokinetics.

[39]  J. W. Stoop,et al.  Serum immunoglobulin levels in healthy children and adults. , 1969, Clinical and experimental immunology.